With a CAGR of 6.1%, the worldwide dronabinol market is expected to rise from USD 184.5 million in 2022 to USD 332.7 million by 2031. Nowadays, North America rules the market.
expanding legalization of medicinal cannabis, increased incidence of chemotherapy-induced nausea and vomiting, and expanding knowledge of the therapeutic advantages of dronabinol are driving consistent increase in the dronabinol industry. Dronabinol is becoming popular as a synthetic version of tetrahydrocannabinol (THC) for controlling AIDS-related anorexia and cancer treatment-related symptoms. Future years should see considerable expansion of the market depending on continuous research on novel uses and formulations.
Market Trend: More study on new delivery methods
Innovative dronabinol delivery techniques like sublingual sprays and transdermal patches are under research to raise bioavailability and patient convenience. Comparatively to conventional oral capsules, these new formulations seek to offer more regulated and continuous medication distribution. The need to improve treatment efficacy and lower negative effects connected with oral administration drives the trend towards other delivery strategies. Investing in R&D, pharmaceutical firms want to create proprietary technologies that set their goods apart in the cutthroat market. The need for various dronabinol formulations is probably going to rise as patients and healthcare professionals search for more customized treatment choices, hence possibly changing the market scene in the next years.
Market Driver: Growing frequency of nausea and vomiting caused by chemotherapy
The main driver for the dronabinol market is the rising cancer incidence as well as the consequent development in chemotherapy therapies. Affecting up to 80% of patients receiving chemotherapy, chemotherapy-induced nausea and vomiting (CINV) still presents a major difficulty in cancer treatment. Particularly in cases when traditional antiemetics are not working, dronabinol has proven effectiveness in controlling CINV. The demand for efficient antiemetic medicines is predicted to expand proportionately as cancer rates rise worldwide thanks in part to aging populations and changing lifestyles. Particularly for patients with refractory CINV, healthcare professionals are realizing dronabinol is a great choice in multimodal antiemetic treatments. As dronabinol gets more included into accepted oncology treatment guidelines, this tendency is probably going to continue market growth.
Market Restraint: Tight legal restrictions and a strict regulating environment
The dronabinol business is seriously challenged by the complicated and variable legal status of cannabis-derived goods throughout different countries. Although dronabinol is a synthetic chemical, its connection to cannabis leads it to tight rules and legal limits in many countries. This regulatory terrain limits product availability, generates obstacles to market entrance, and complicates cross-border trade. Dronabinol is still listed as a prohibited substance in several nations, which calls for particular permissions for distribution and prescription writing. These legal nuances can discourage pharmaceutical companies from funding dronabinol research and development, so perhaps slowing down market expansion. Furthermore, the stigma connected with cannabis-related goods could affect prescriber and patient attitudes, therefore restricting the development of the industry in some areas.
Oral Solution Part to See Fast Development
In the next years, the portion of the dronabinol market dedicated to oral solutions is predicted to show notable increase. For people with swallowing problems especially, this formulation provides better absorption and simpler administration than capsules. More exact dosing made possible by the liquid form is absolutely vital for properly controlling symptoms and reducing unwanted effects. Oral solutions are probably going to take front stage as patient tastes move toward more flexible and convenient dosing choices. Further improving the palatability and stability of dronabinol oral solutions and so increasing their acceptance among patients and healthcare professionals is continuous investigation into flavor masking technology and new excipients.
America Dominate North America Owing to a favorable regulatory environment
With the United States driving most of regional development, North America presently leads the world in dronabinol sales. A well-established healthcare infrastructure, more knowledge among patients and healthcare professionals, and a more favorable legislative climate for cannabis-derived medications help to explain the region's supremacy. Widespread acceptance and integration into treatment guidelines have come from the U.S. Food and Drug Administration's approval of dronabinol for particular uses. Furthermore confirming North America's position are important market players and continuous clinical research conducted in the area. By raising general understanding and acceptance of cannabis-based treatments, the expanding trend of medical cannabis legalization throughout different states is also predicted to indirectly boost the dronabinol business. Market development in this area is probably going to quicken in the next years as reimbursement rules change and more insurance companies start to cover dronabinol for recognized uses.
Established pharmaceutical businesses mixed with new players focused in cannabinoid-based treatments define the dronabinol industry. Important tactics used by market players are strategic alliances for market expansion, R&D investments in new formulations and delivery technologies, and attempts to get regulatory approvals in different areas. Additionally joining the market are generic producers, therefore increasing the competitiveness and maybe lowering pricing. To keep their market share, companies are turning more and more toward differentiation via better formulations, combo treatments, and enlarged indications. Regional differences in laws and market access also affect the competitive scene; businesses modify their plans to negotiate the complicated legal and regulatory framework surrounding cannabis-derived medications.
AbbVie Inc.
Insys Therapeutics, Inc.
GW Pharmaceuticals plc
Valeant Pharmaceuticals International, Inc.
Bausch Health Companies Inc.
Akorn, Inc.
Unimed Pharmaceuticals, LLC
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Merck & Co., Inc.
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2022- 2031)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global Dronabinol Market (2018 – 2022)
3.2. Global Dronabinol Market (2023 – 2031)
3.2.1. Market Segment By Type (2023 – 2031)
3.2.2. Market Segment By Application (2023 – 2031)
3.2.3. Market Segment By Distribution Channel (2023 – 2031)
3.2.4. Market Segment By End User (2023 – 2031)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Increasing research on novel delivery systems
4.1.2. Growing acceptance of medical cannabis
4.1.3. Expansion of indications for dronabinol use
4.2. Market Drivers
4.2.1. Rising prevalence of chemotherapy-induced nausea and vomiting
4.2.2. Increasing legalization of medical cannabis
4.2.3. Growing geriatric population and associated health conditions
4.3. Market Restraints
4.3.1. Strict regulatory environment and legal barriers
4.3.2. Side effects and potential for abuse
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY TYPE (MARKET VALUE (US$ MILLION) – 2022-2031*)
5.1. Oral Solution
5.2. Capsule
6. BY APPLICATION
6.1. Antiemetic
6.2. Appetite Stimulant
6.3. Others
7. BY DISTRIBUTION CHANNEL
7.1. Hospital Pharmacies
7.2. Retail Pharmacies
7.3. Online Pharmacies
8. BY END USER
8.1. Hospitals
8.2. Clinics
8.3. Home Healthcare
9. GEOGRAPHY
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. South America
9.2.1. Brazil
9.2.2. Argentina
9.2.3. Rest of South America
9.3. Europe
9.3.1. Germany
9.3.2. United Kingdom
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle-East
9.5.1. UAE
9.5.2. Saudi Arabia
9.5.3. Turkey
9.5.4. Rest of Middle East
9.6. Africa
9.6.1. South Africa
9.6.2. Egypt
9.6.3. Rest of Africa
10. COMPETITVE LANDCAPE
10.1. Key Developments
10.2. Company Market Share Analysis
10.3. Product Benchmarking
11. SWOT ANALYSIS
12. COMPANY PROFILES
12.1. AbbVie Inc.
12.2. Insys Therapeutics, Inc.
12.3. GW Pharmaceuticals plc
12.4. Valeant Pharmaceuticals International, Inc.
12.5. Bausch Health Companies Inc.
12.6. Akorn, Inc.
12.7. Unimed Pharmaceuticals, LLC
12.8. Mylan N.V.
12.9. Teva Pharmaceutical Industries Ltd.
12.10. Merck & Co., Inc.
12.11. Solvay Pharmaceuticals
12.12. Par Pharmaceutical
13. MARKET OPPORTUNITIES
By Type:
Oral Solution
Capsule
By Application:
Antiemetic
Appetite Stimulant
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By End User:
Hospitals
Clinics
Home Healthcare
By Region:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
